COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.ob - News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce its acquisition of The Kaneabis Brand through its parent company Cannabis Consulting Inc. Cannabis Science is also proud to announce that Robert Kane has been promoted to the position of Vice President of Investor Relations, Mr. Robert Kane is in the process of relocating to Colorado Springs to help facilitate opening up the new Cannabis Science headquarters in Colorado Springs, Colorado.
Cannabis Science embraces Mr. Kane and his Kaneabis Brand. Each one of Mr. Kane's endeavors falls directly in line with Cannabis Science’s mission to establish the Medical Cannabis Industry as a viable pharmaceutical/nutraceutical business model and investment alternative for all investors.
For over a decade Robert J. Kane worked for Stifel Nicolaus (NYSE: SF) as a registered representative. Recognizing the Medical Cannabis Industry’s opportunity Mr. Kane left Stifel Nicolaus and began consulting Medical Cannabis Industry leaders mostly with business plans to support investment in the industry, and the Kaneabis brand was born. Today, Mr. Kane, along with Cannabis Science, will educate conservative Wall Street that Cannabis is a viable alternative investment opportunity that will also help improve the health of mankind.
This Cannabis Science acquisition includes but not limited to;
a. All contracted rights, properties, patents, trademarks, and distribution rights and agreements pertaining to its Cannabis Consulting Inc.
b. Robert Kane Partners
c. Kaneabis Consulting
d. Kaneabis Fund
e. Kaneabis Report
f. Kaneabis Radio
Dr. Robert Melamede Ph.D., Cannabis Science President & CEO, stated, “For the last 6 months we have been working with Mr. Kane on a consulting basis and have been extremely pleased with his work ethic, expertise, and dedication to promoting the global 'cannabis awakening'. We have received a lot of positive feedback from shareholders, and we believe bringing Mr. Kane and his resources exclusively into the Cannabis Science business model is a good decision. It will better serve the needs of our shareholders and add additional revenue to our bottom line through the expanded line of services that we can now offer. These revenues, along with revenues generated from our other profit centers, should improve our balance sheet and give us access to the additional capital required to complete the FDA approval process.”
ABOUT ROBERT KANE
Robert Kane’s professional career begins with a nomination by the Somerset County, New Jersey Chamber of Commerce for "Outstanding Business Person of the Year" at the age of 16. Inspired and ambitious, Mr. Kane then earned the "Isabella Cannon Leadership Scholarship," and attended Elon University, North Carolina.
Robert’s early focus and expertise was in sales, as he was a Thomas Nelson bookman in college spending a college summer selling books and bibles door to door in Georgia through the college internship program with Thomas Nelson Corporation (Nashville, TN). These sales talents earned Robert success in many businesses from his uncles jewelry store Roy T Jewelers (Piscataway, NJ), a Board Member of an Executive Fitness Club, and as a mortgage broker between college and when he first started at Ryan, Beck & Company, which eventually became Stifel Nicolaus (NYSE: SF).
Mr. Kane acted as Chairman of the Board for the Write Note foundation, as well as served on the board of the National Single Parent Resource Center. He served on the organizational committee for the Pajama Program – which was once featured on Oprah - and has participated in many charity events including a “Walk a Mile in Her Shoes” for the International Women's Domestic Abuse Council.
Eternally observing for new investment prospects, Robert then focused his attention on an emerging Cannabis Industry. After serving 11 years as a registered representative with Stifel Nicolaus (NYSE:SF), Robert established Cannabis Consulting Inc., at the dawn of 2010.
Mesmerized by the sheer potential of the burgeoning Cannabis Industry, Robert set out on a speaking tour, initially funded with a small loan from a family member and the supported operationally with the writing of business plans, sales consulting, and investor relations. Robert’s breaks in the industry was through participating as a panelist in the Los Angeles Medical Marijuana Expo, Hawaii's First Medical Marijuana Conference, KushCon II in Denver, The Marijuana Conference in San Francisco, New Jersey's 1st Cannabis Expo, and the Green Relief Expo. He sheds new light on an industry caught in a grey area; he is a leading proponent for introducing would-be investors to one of the most flourishing industries since the invention of the smart phone.
Robert Kane has written articles for Cannabis Times and MJ Business Daily. Robert was a joint host with Casper Leitch in Time4Hemp ‘Taxing Monday’s” in support of the organization 280e Reform. www.280ereform.org.
Robert established the Medical Cannabis Index nicknamed the MCANI, and blueprinted a private equity fund, The Kaneabis Fund which drew the attention of the Wall Street Journal http://online.wsj.com/article/SB10001424052748704677404576285011036650834.html
As Medical Cannabis continues spreading from one state to the next, Robert continues offering a viable investment alternative for the more courageous and daring investors.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.